PTPN11 and acute myeloid leukemia: Furthermore, PTPN11 and other RAS/RTK-pathway gene mutations have been associated with resistance-development to venetoclax/azacitidine treatment and poor outcome [62], indicating the high medical need for novel treatment approaches for PTPN11-mutant AML.